Logo for Regenxbio Inc

Regenxbio Investor Relations Material

Latest events

Logo for Regenxbio Inc

Q4 2024

Regenxbio
Logo for Regenxbio

Q4 2024

13 Mar, 2025
Logo for Regenxbio

Q3 2024

6 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Regenxbio Inc

Access all reports
REGENXBIO is a clinical-stage biotechnology company that provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.